NCT05081518 is a Phase 1 clinical trial of Lu AG06466 in Focal Epilepsy, sponsored by H. Lundbeck A/S.

Who is sponsoring NCT05081518?

NCT05081518 is sponsored by H. Lundbeck A/S.

What drugs are being tested in NCT05081518?

Interventions in NCT05081518: Lu AG06466, Placebo.

What condition does NCT05081518 study?

NCT05081518 studies Focal Epilepsy.

Is NCT05081518 still recruiting?

NCT05081518 is currently terminated. Last updated 9 November 2022.

Last reviewed 2022-11-09 · How we verify

NCT05081518

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

Terminated Phase 1 Last updated 9 November 2022

What this trial tests

Phase 1 trial testing Lu AG06466 in Focal Epilepsy in 1 participant. Terminated before completion.

Timeline

29 September 2021

Primary endpoint
14 April 2022

14 April 2022

Quick facts

Lead sponsor	H. Lundbeck A/S
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	1
Start date	29 September 2021
Primary completion	14 April 2022
Estimated completion	14 April 2022
Sites	1 location across United States

Drugs / interventions tested

Lu AG06466 — full drug profile →
Placebo

Conditions studied

Focal Epilepsy — all drugs for Focal Epilepsy →

Sponsor

H. Lundbeck A/S — full company profile →

Who can join

Adults 18 to 60, any sex, with Focal Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to investigate effects of Lu AG06466 on seizure activity after increasing daily doses during 4 weeks in participants with an implanted responsive neurostimulation system.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.
Maccarrone M, Di Marzo V, Gertsch J, Grether U, et al · · 2023 · cited 128× · PMID 37164640 · DOI 10.1124/pharmrev.122.000600
Epilepsy Characteristics in Neurodevelopmental Disorders: Research from Patient Cohorts and Animal Models Focusing on Autism Spectrum Disorder.
Chakraborty S, Parayil R, Mishra S, Nongthomba U, et al · · 2022 · cited 18× · PMID 36142719 · DOI 10.3390/ijms231810807

Verify or expand the search:

Other trials of Lu AG06466

Trials testing the same drug.

NCT05219838 — Binding and Effects of Lu AG06466 in the Brain of Healthy Men · Phase 1 · completed
NCT05177029 — Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants · Phase 1 · terminated
NCT04990219 — A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis · Phase 1 · terminated
NCT04974359 — A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia · Phase 1 · terminated
NCT04713254 — Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men · Phase 1 · completed

Other recruiting trials for Focal Epilepsy

Currently open trials in the same condition.

NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07193277 — Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy · Phase 4 · recruiting
NCT07139457 — Wearable Epileptic Seizure Prediction and Alert Glasses Based on Neuromorphic Computing · NA · active not recruiting
NCT06210022 — Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy · recruiting
NCT05981755 — Breathing Rescue for SUDEP Prevention · NA · recruiting

Other H. Lundbeck A/S trials

Trials by the same sponsor.

NCT07514858 — A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations · Phase 2 · not yet recruiting
NCT07513441 — A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) · Phase 1 · not yet recruiting
NCT06701526 — A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications · Phase 4 · active not recruiting
NCT06706622 — A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) · Phase 3 · active not recruiting
NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05081518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lundbeck A/S
Last refreshed: 9 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05081518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing